Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Up 13.5% in June

Athira Pharma, Inc. (NASDAQ:ATHA) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totalling 1,010,000 shares, an increase of 13.5% from the May 31st total of 889,500 shares. Approximately 2.9% of the shares of the stock are short sold. Based on an average daily volume of 173,900 shares, the days-to-cover ratio is presently 5.8 days.

Analysts Set New Price Targets

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $19.00 price objective on shares of Athira Pharma in a research note on Thursday, June 20th.

Insider Activity at Athira Pharma

In other Athira Pharma news, Director Kelly A. Romano bought 27,400 shares of the stock in a transaction on Monday, June 24th. The stock was purchased at an average price of $2.42 per share, with a total value of $66,308.00. Following the completion of the purchase, the director now owns 80,715 shares in the company, valued at $195,330.30. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In other Athira Pharma news, Director Kelly A. Romano bought 15,000 shares of the stock in a transaction on Friday, June 21st. The stock was purchased at an average price of $2.26 per share, with a total value of $33,900.00. Following the completion of the purchase, the director now owns 53,315 shares in the company, valued at $120,491.90. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Kelly A. Romano bought 27,400 shares of the stock in a transaction on Monday, June 24th. The shares were acquired at an average cost of $2.42 per share, with a total value of $66,308.00. Following the purchase, the director now owns 80,715 shares of the company’s stock, valued at approximately $195,330.30. The disclosure for this purchase can be found here. 19.80% of the stock is owned by insiders.

Institutional Trading of Athira Pharma

Several institutional investors have recently added to or reduced their stakes in the stock. Forefront Analytics LLC boosted its holdings in Athira Pharma by 43.0% in the fourth quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock valued at $72,000 after acquiring an additional 8,955 shares during the last quarter. Private Advisor Group LLC bought a new stake in Athira Pharma in the fourth quarter valued at approximately $32,000. Clarius Group LLC boosted its holdings in Athira Pharma by 35.8% in the fourth quarter. Clarius Group LLC now owns 53,551 shares of the company’s stock valued at $130,000 after acquiring an additional 14,124 shares during the last quarter. Mirador Capital Partners LP bought a new stake in Athira Pharma in the first quarter valued at approximately $57,000. Finally, Laird Norton Trust Company LLC boosted its holdings in Athira Pharma by 21.3% in the third quarter. Laird Norton Trust Company LLC now owns 178,709 shares of the company’s stock valued at $361,000 after acquiring an additional 31,400 shares during the last quarter. 57.12% of the stock is currently owned by institutional investors.

Athira Pharma Stock Performance

Shares of Athira Pharma stock traded up $0.02 on Wednesday, hitting $2.54. The stock had a trading volume of 62,644 shares, compared to its average volume of 294,501. The stock has a 50 day moving average of $2.39 and a 200 day moving average of $2.72. Athira Pharma has a twelve month low of $1.33 and a twelve month high of $4.30. The firm has a market capitalization of $97.36 million, a P/E ratio of -0.87 and a beta of 2.91.

Athira Pharma (NASDAQ:ATHA) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.11. Equities analysts expect that Athira Pharma will post -2.79 earnings per share for the current year.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.